Immunic, Inc. (IMUX) Announces European Patent Grant for Vidofludimus Calcium

Immunic, Inc. (NASDAQ:IMUX) is one of the 11 Best High Volume Penny Stocks to Buy Now. On March 10, 2026, Immunic, Inc. (NASDAQ:IMUX) announced that the European Patent Office granted a key patent covering label-relevant dosing regimens for its lead asset, vidofludimus calcium. The patent is expected to protect Europe through 2038 and may be eligible for a Supplementary Protection Certificate, which could extend exclusivity to as late as 2043.

Immunic, Inc. (NASDAQ:IMUX) noted that the claims broadly cover vidofludimus and its salt, solvate, and free acid forms across all label-relevant dosing regimens, meaning protection is not limited to a single formulation and may extend to alternative forms used according to the approved label. The patent had previously been granted in the United States in 2023.Immunic, Inc. (IMUX) Announces European Patent Grant for Vidofludimus Calcium

Copyright: zneb076 / 123RF Stock Photo

On March 2, 2026, H.C. Wainwright lowered its price target on Immunic, Inc. (NASDAQ:IMUX) to $5 from $8 previously and maintained a Buy rating after updating its model.

Immunic, Inc. (NASDAQ:IMUX) develops oral immunology therapies targeting chronic inflammatory and autoimmune diseases, including multiple sclerosis and ulcerative colitis.

While we acknowledge the potential of IMUX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.

View Comments